黑色素瘤是臨床上常見(jiàn)的皮膚惡性腫瘤,且發(fā)病率呈逐年增加的趨勢(shì).該病惡性程度高,易發(fā)生轉(zhuǎn)移.全球新批準(zhǔn)并上市的治療黑色素瘤的治療藥物有威羅菲尼、達(dá)拉菲尼、曲美替尼、易普利姆瑪、nivolumab 以及pembrolizumab,處于研發(fā)后期的黑色素瘤治療藥物有cobimetinib、binimetinib、talimogene laherparepvec、貝伐單抗、seviprotimut-L、NGcGM3/VSSP 以及c-Kit 抑制劑甲磺酸伊馬替尼等.對(duì)近年來(lái)上市和處于研發(fā)后期的黑色素瘤的治療藥物進(jìn)行了詳細(xì)介紹,同時(shí)對(duì)其未來(lái)發(fā)展方向進(jìn)行了展望,以期為黑色素瘤治療藥物的研發(fā)指明方向,給黑色素瘤患者帶來(lái)希望.

Melanoma is the clinical common skin malignant tumor, and its incidence rate has increased year by year. The malignant degree of melanoma is high, and easy to shift. Melanoma drugs approved for sale include zelboraf, dabrafenib, trametinib, ipilimumab, nivolumab, and pembrolizumab. Melanoma drugs under development include cobimetinib, binimetinib, talimogene laherparepvec, bevacizumab, seviprotimut-L, NGcGM3/VSSP, and c-Kit inhibitor imatinib mesylate. Melanoma drugs (launched and R & D) are introduced, and the future development direction of melanoma drugs is prospected in this paper, in order to provide a basis for melanoma drugs, and give hope for melanoma patients.